Thomas Saphner1, Andy Marek2, Jennifer K Homa2, Lisa Robinson3, Neha Glandt4. 1. Aurora NCORP, Advocate Aurora Health, 960 N 12th St., Milwaukee, WI 53233, United States of America. Electronic address: Thomas.Saphner@aah.org. 2. Advocate Aurora Research Institute, Advocate Aurora Health, 960 N 12th St., Milwaukee, WI 53233, United States of America. 3. Aurora Clinical Data Registries, Advocate Aurora Health, 960 N 12th St., Milwaukee, WI 53233, United States of America. 4. Aurora NCORP, Advocate Aurora Health, 960 N 12th St., Milwaukee, WI 53233, United States of America.
Abstract
INTRODUCTION: Individual demographic data and socioeconomic status (SES) factors from Census block group data may help define groups with disadvantaged access to clinical trials. METHODS: Individual demographic data from the Aurora Cancer Registry and SES factors corresponding to the Census block group of the patient's address were studied for a six-year period ending July 31, 2019. RESULTS: The final study cohort included 39,968 patients (enrolled = 772, and not enrolled = 39,196). In univariate analysis, significantly fewer patients older than age 65 (p < 0.001) and fewer men (p < 0.001) were enrolled in clinical trials. Socioeconomic factors found to be significant during univariate analysis included: low household income (p < 0.001), percentage below the poverty line (p < 0.001), low percentage home ownership (p = 0.006), unemployment (p = 0.003), absence of a college degree (p = 0.037) and absence of a high school degree (p = 0.007). In multivariate analysis, patients older than age 65 were less likely to participate in a trial (odds ratio 0.574, p < 0.001) and men were less likely to participate (odds ratio = 0.703, p < 0.001). Only 1.4% of the variance in clinical trial participation was accounted for demographic and SES factors. CONCLUSIONS: The only groups with disadvantaged access to clinical trials in our institution were the elderly and men. Whether demographic or SES factors are related to accrual rates of clinical trials in other geographic regions or in other types of research studies warrants further investigation.
INTRODUCTION: Individual demographic data and socioeconomic status (SES) factors from Census block group data may help define groups with disadvantaged access to clinical trials. METHODS: Individual demographic data from the Aurora Cancer Registry and SES factors corresponding to the Census block group of the patient's address were studied for a six-year period ending July 31, 2019. RESULTS: The final study cohort included 39,968 patients (enrolled = 772, and not enrolled = 39,196). In univariate analysis, significantly fewer patients older than age 65 (p < 0.001) and fewer men (p < 0.001) were enrolled in clinical trials. Socioeconomic factors found to be significant during univariate analysis included: low household income (p < 0.001), percentage below the poverty line (p < 0.001), low percentage home ownership (p = 0.006), unemployment (p = 0.003), absence of a college degree (p = 0.037) and absence of a high school degree (p = 0.007). In multivariate analysis, patients older than age 65 were less likely to participate in a trial (odds ratio 0.574, p < 0.001) and men were less likely to participate (odds ratio = 0.703, p < 0.001). Only 1.4% of the variance in clinical trial participation was accounted for demographic and SES factors. CONCLUSIONS: The only groups with disadvantaged access to clinical trials in our institution were the elderly and men. Whether demographic or SES factors are related to accrual rates of clinical trials in other geographic regions or in other types of research studies warrants further investigation.
Authors: Mariana C Arcaya; Reginald D Tucker-Seeley; Rockli Kim; Alina Schnake-Mahl; Marvin So; S V Subramanian Journal: Soc Sci Med Date: 2016-08-28 Impact factor: 4.634
Authors: Joseph M Unger; Dawn L Hershman; Kathy S Albain; Carol M Moinpour; Judith A Petersen; Kenda Burg; John J Crowley Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol Journal: J Oncol Pract Date: 2013-10-15 Impact factor: 3.840
Authors: David Wendler; Raynard Kington; Jennifer Madans; Gretchen Van Wye; Heidi Christ-Schmidt; Laura A Pratt; Otis W Brawley; Cary P Gross; Ezekiel Emanuel Journal: PLoS Med Date: 2005-12-06 Impact factor: 11.069
Authors: Zachary Feuer; Richard S Matulewicz; Ramsankar Basak; Donna A Culton; Kimberly Weaver; Kristalyn Gallagher; Tracy L Rose; Matthew Milowsky; Marc A Bjurlin Journal: Contemp Clin Trials Date: 2022-02-22 Impact factor: 2.261